A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer (AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85 mg m(-2) on day 1, FA 200 mg m(-2) as a 2 h infusion followed by bolus 5-FU 400 mg m(-2) and a 22 h infusion of 5-FU 600 mg m(-2), repeated for 2 consecutive days every 2 weeks. All patients were assessable for toxicity and response to treatment. Four (7%) complete responses and 19 partial responses were observed (overall response rate, 38%). Stable disease was observed in 22 (36%) patients, with progressive disease in the other six (10%) patients. Median time to progression (TTP) and median overall survival (OS) were 7.1 and 11.2 months, respectively. National Cancer Institute Common Toxicity Criteria grade 3 and 4 haematologic toxicities were neutropenia, anaemia and thrombocytopenia in 36, 10 and 5% of the patients, respectively. Grade 3 peripheral neuropathy was recorded in three (5%) patients. FOLFOX-4 is an active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“It has been registered worldwide for the treatment of advanced colorectal cancer, where, in association with 5-FU, it was reported to yield a response rate of 36–58% (Levi et al, 1992; Levi et al, 1994; De Gramont et al, 2000).”
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 2×
“The two-stage minimax design for phase II trial of Simon (1989) was adopted, selecting an alpha error1⁄4 0.”
InfluentialRising incidence of adenocarcinoma of the esophagus and gastric cardia
Blot, W. J. (1991) · JAMA · doi:10.1001/jama.265.10.1287 · Cited by 2,354
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 870
Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P.-O., Haglund, U., Svensson, C., Enander, L.-K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 849 · cited 1×
“However, in randomised trials, chemotherapy was demonstrated to result in both a significant survival advantage and an improved quality of life when compared to best supportive care (Murad et al, 1993; Pyrhonen et al, 1995; Glimelius et al, 1997).”
Pyrhönen, S., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.114 · Cited by 789 · cited 1×
“However, in randomised trials, chemotherapy was demonstrated to result in both a significant survival advantage and an improved quality of life when compared to best supportive care (Murad et al, 1993; Pyrhonen et al, 1995; Glimelius et al, 1997).”
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643 · cited 1×
“Recently, oxaliplatin, a thirdgeneration platinum compound with the 1,2-diaminocyclohexane (DACH) carrier ligand, has entered the clinical practice, showing a different toxicity profile, with neurotoxicity being the doselimiting toxicity (Extra et al, 1990; Raymond et al, 1998).”
Vanhoefer, U., Rougier, P., Wilke, H., Ducreux, M. P., Lacave, A. J., Van Cutsem, E., Planker, M., Santos, J. G. D., Piedbois, P., Paillot, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2648 · Cited by 531 · cited 2×
“No patient had received prior radiotherapy, while 10 patients had received adjuvant chemotherapy with 5-FU and folinic acid according to the Machover regimen following radical surgery.”
Lévi, F. A., Zidani, R., Vannetzel, J.-M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., et al. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.21.1608 · Cited by 396 · cited 1×
“It has been registered worldwide for the treatment of advanced colorectal cancer, where, in association with 5-FU, it was reported to yield a response rate of 36–58% (Levi et al, 1992; Levi et al, 1994; De Gramont et al, 2000).”
Wils, J., Klein, H. O., Wagener, D. J. T., Bleiberg, H., Reis, H. E., Korsten, F. W., Conroy, T., Fickers, M. M. F., Leyvraz, S., & Buyse, M. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.827 · Cited by 388 · cited 2×
“No patient had received prior radiotherapy, while 10 patients had received adjuvant chemotherapy with 5-FU and folinic acid according to the Machover regimen following radical surgery.”
Cited by
Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9378 · Cited by 782
Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 365
Zhang, H., Liu, H., Shen, Z., Lin, C., Wang, X., Qin, J., Qin, X., Xu, J., & Sun, Y. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002058 · Cited by 207
Kwon, H.-C., Roh, M. S., Oh, S. Y., Kim, S.-H., Kim, M. C., Kim, J.-S., & Kim, H.-J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl430 · Cited by 200
“The oxaliplatin/5-FU combination has proven to be an effective first- or second-line treatment of advanced colorectal cancer [10, 11], and the preliminary results of several recent studies indicate that various combinations of oxaliplatin and 5-FU may be as effective in gastric cancer [12–14].”
BackgroundResult
Metadata
- Authors
- De Vita, F., Orditura, M., Matano, E., Bianco, R., Carlomagno, C., Infusino, S., Damiano, V, Simeone, E., Diadema, M. R., Lieto, E., Castellano, P., Pepe, S., De Placido, S., Galizia, G., Di Martino, N., Ciardiello, F., Catalano, G., & Bianco, A. R.
- Venue
- British Journal of Cancer
- Published
- 2005-04-26
- Volume
- 92
- Issue
- 9
- Pages
- 1644-1649
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2060704373
- Cited by
- 179
- References
- 17
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.